Loading clinical trials...
Loading clinical trials...
An Open Study of the Safety, Tolerability and Immunogenicity of the "Gam-COVID-Vac"Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years
Conditions
Interventions
Gam-COVID-Vac
Locations
1
Russia
Federal state budgetary institution "Central clinical hospital with polyclinic" Of the office Of the President of the Russian Federation
Moscow, Russia
Start Date
October 22, 2020
Primary Completion Date
March 30, 2021
Completion Date
April 30, 2021
Last Updated
January 22, 2021
NCT06631287
NCT04885504
NCT04510025
NCT04326426
NCT05655351
NCT04610515
Lead Sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions